IL162448A0 - Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor - Google Patents

Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor

Info

Publication number
IL162448A0
IL162448A0 IL16244802A IL16244802A IL162448A0 IL 162448 A0 IL162448 A0 IL 162448A0 IL 16244802 A IL16244802 A IL 16244802A IL 16244802 A IL16244802 A IL 16244802A IL 162448 A0 IL162448 A0 IL 162448A0
Authority
IL
Israel
Prior art keywords
csf
biologically active
stimulating factor
colony stimulating
granulocyte colony
Prior art date
Application number
IL16244802A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of IL162448A0 publication Critical patent/IL162448A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL16244802A 2001-12-19 2002-12-05 Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor IL162448A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100322A SI21102A (sl) 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
PCT/EP2002/013810 WO2003051922A1 (en) 2001-12-19 2002-12-05 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
IL162448A0 true IL162448A0 (en) 2005-11-20

Family

ID=20433022

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16244802A IL162448A0 (en) 2001-12-19 2002-12-05 Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor
IL162448A IL162448A (en) 2001-12-19 2004-06-10 Process for the purification and isolation of biologically active granulocyte colony stimulating factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162448A IL162448A (en) 2001-12-19 2004-06-10 Process for the purification and isolation of biologically active granulocyte colony stimulating factor

Country Status (21)

Country Link
US (1) US20050159589A1 (de)
EP (2) EP1458757B1 (de)
JP (1) JP4454311B2 (de)
KR (1) KR20040071212A (de)
CN (1) CN1606568A (de)
AT (1) ATE423136T1 (de)
AU (1) AU2002366275B2 (de)
BR (1) BR0215191A (de)
CA (1) CA2469984C (de)
DE (1) DE60231243D1 (de)
HR (1) HRP20040572A2 (de)
HU (1) HUP0402547A3 (de)
IL (2) IL162448A0 (de)
MX (1) MXPA04006076A (de)
NO (1) NO20042967L (de)
NZ (1) NZ533305A (de)
PL (1) PL207775B1 (de)
RU (1) RU2358980C2 (de)
SI (2) SI21102A (de)
WO (1) WO2003051922A1 (de)
ZA (1) ZA200404291B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
ATE322506T1 (de) * 2004-01-19 2006-04-15 Ares Trading Sa Verfahren zur reinigung von in bakterien exprimierten proteinen
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
EP1856147A4 (de) * 2005-02-15 2008-07-02 Apollo Life Sciences Ltd Molekül und chimere moleküle davon
US20080171857A1 (en) * 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1878739A1 (de) * 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. Einstufige IMAC (MCAC) Aufreinigung von Proteinen
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US8546328B2 (en) 2007-08-27 2013-10-01 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP2009073819A (ja) * 2007-08-29 2009-04-09 Fujifilm Corp 生理活性物質の精製方法
WO2010146599A1 (en) * 2009-06-16 2010-12-23 Lupin Limited Process for purification of recombinant human granulocyte colony stimulating factor
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
EP2552948B1 (de) * 2010-03-30 2016-07-13 Octapharma AG Verfahren zur reinigung des wachstumsfaktorproteins g-csf
EP2691411B1 (de) 2011-03-29 2020-02-26 GlaxoSmithKline LLC Puffersystem zur proteinreinigung
CN103215340A (zh) * 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (de) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Menschlicher granuloxcyt-kolonie-stimulierungsfaktor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
EP0719860B1 (de) * 1988-05-13 2009-12-16 Amgen Inc. Verfahren zur Isolierung und Reinigung von G-CSF
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en) 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
FR2796071B1 (fr) * 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes

Also Published As

Publication number Publication date
CN1606568A (zh) 2005-04-13
SI1458757T1 (sl) 2009-10-31
IL162448A (en) 2010-12-30
PL207775B1 (pl) 2011-01-31
CA2469984C (en) 2014-05-20
WO2003051922A1 (en) 2003-06-26
HUP0402547A2 (hu) 2005-03-29
KR20040071212A (ko) 2004-08-11
CA2469984A1 (en) 2003-06-26
RU2004121982A (ru) 2005-04-20
BR0215191A (pt) 2004-11-16
NO20042967L (no) 2004-09-07
HK1064681A1 (en) 2005-02-04
HUP0402547A3 (en) 2010-01-28
EP1458757B1 (de) 2009-02-18
MXPA04006076A (es) 2005-02-24
RU2358980C2 (ru) 2009-06-20
AU2002366275B2 (en) 2009-04-02
ZA200404291B (en) 2005-08-05
HRP20040572A2 (en) 2005-06-30
NZ533305A (en) 2005-11-25
JP2005525304A (ja) 2005-08-25
SI21102A (sl) 2003-06-30
JP4454311B2 (ja) 2010-04-21
EP2053061A1 (de) 2009-04-29
ATE423136T1 (de) 2009-03-15
AU2002366275A1 (en) 2003-06-30
US20050159589A1 (en) 2005-07-21
PL369669A1 (en) 2005-05-02
DE60231243D1 (de) 2009-04-02
EP1458757A1 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
IL162448A (en) Process for the purification and isolation of biologically active granulocyte colony stimulating factor
SI1492878T1 (sl) Postopek za pripravo Ĺľelenega profila gliko-izoform eritropoietina
KR960007612A (ko) 재조합 사람 혈청 알부민의 정제방법
ATE403671T1 (de) Methoden zur aufreinigung von rekombinatem humanem erythropoietin aus zellkulturüberständen
AU2007301436B2 (en) Organic-inorganic hybrid chiral sorbent and process for the preparation thereof
SK8592002A3 (en) Process for the purification of pharmacologically active proteins
DE58903791D1 (de) Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung.
SI1753778T1 (sl) Postopek za čiščenje eritropoetina
DK1714982T3 (da) Fremgangsmåde til rensning af stærkt anioniske proteiner
IL175350A0 (en) Method for the production of statins
CA2210990A1 (en) New combined process for the purification of vancomycin hydrochloride
Ogura et al. An efficient 1, 3-asymmetric induction accompanied with epimerization at the 2-position. Stereoselective reduction of α-substituted β-keto sulfoxides under basic conditions
US4627919A (en) Resolving agent
EP1568705A4 (de) Verfahren und apparat zum einengen und zur aufreinigung von nukleinsäure
DE69001309D1 (de) Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist.
ATE401298T1 (de) Verbessertes verfahren zur herstellung von 2s,3s- n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
CA2245080A1 (en) Process for the preparation of heteroarylcarboxylic amides and esters
NO20052916L (no) Fremgangsmate for rensingen av TNF-bindende proteiner ved anvendelse av IMAC
AU2002366765A1 (en) Process for producing diene compound
EP1178114A3 (de) Hitzestabile D-Aminoacylase
Kim et al. Purification and Characterization of $\beta $-Xylosidase from Trichoderma sp. SY
CA2261144A1 (en) Improvements in the synthesis of annamycin
KR960017519A (ko) 폐산을 이용한 고순도 염화제일철 수용액의 제조방법
WO2025186218A8 (en) Purification and analysis of rna
Kishikawa et al. Enantioseparation of N-(1-arylethyl) amides and α-[N-(3, 5-dinitrobenzoyl)] amino esters by column chromatography. Chiral recognition using a hydrogen bond acceptor centered in a pseudo-C2 symmetric environment. 2